

Genetic Factors and their Impact on Breast Cancer Risk

Luis Elian*

Department of Medicine, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA

Introduction

Breast cancer is a complex and multifaceted disease that arises from the abnormal growth of cells in the breast tissue. Its development involves a series of genetic, environmental, and hormonal factors that interact in various ways. Understanding the role of these factors in breast cancer development is crucial for improving prevention, diagnosis, and treatment strategies. This overview will delve into the key aspects that contribute to breast cancer development, including genetic mutations, hormonal influences, and environmental factors. Genetic predispositions refer to the increased likelihood of developing a disease due to specific genetic variations inherited from one's parents. In breast cancer, several genes have been identified that significantly elevate the risk of developing the disease. These genes can be broadly categorized into high-penetrance genes, moderate-penetrance genes, and low-penetrance genes, depending on the degree of risk they confer [1]. The most well-known high-penetrance genes associated with breast cancer are ductal carcinoma and lobules of the breast. Mutations in these genes are responsible for a substantial proportion of hereditary breast cancer cases. Women with ductal carcinoma or lobules of the breast mutations have a significantly higher risk of developing breast cancer compared to the general population. Ductal carcinoma and lobules of the breast are tumour suppressor genes involved in DNA repair mechanisms. When these genes are mutated, the ability to repair DNA damage is compromised, leading to genomic instability and increased cancer risk. Ductal carcinoma mutations are also associated with a higher likelihood of developing triple-negative breast cancer, a particularly aggressive form of the disease [2]. Another high-penetrance gene linked to breast cancer is TP53, which encodes the p53 protein. P53 is known as the "guardian of the genome" because of its role in maintaining genomic integrity. Mutations in TP53 are associated with Li-Fraumeni syndrome, a hereditary condition that significantly increases the risk of various cancers, including breast cancer. Women with TP53 mutations have a lifetime breast cancer risk of up to 85%.

Diet, physical activity, and alcohol consumption can impact breast cancer risk. For example, excessive alcohol intake and obesity are associated with a higher risk of developing breast cancer. Women with PALB2 mutations have a breast cancer risk that is approximately three to four times higher than the general population [3]. CHEK2 is a gene that encodes a protein involved in DNA damage response and cell cycle control. Mutations in CHEK2 are associated with a moderate increase in breast cancer risk. The most common CHEK2 mutation, 1100delC, is particularly prevalent in certain populations, such as those of Northern and Eastern European descent. Women with this mutation have a twofold to threefold increased risk of breast cancer [4]. Low-penetrance genes individually contribute to a smaller increase in breast cancer risk but can collectively have a significant impact. These genes often involve Single Nucleotide Polymorphisms (SNPs) that are common in the population. While each SNP may only slightly elevate the risk, the presence of multiple risk alleles can compound the overall risk. The identification of genetic predispositions to

breast cancer has significant implications for patient care. Genetic testing can identify individuals with mutations in high- and moderate-penetrance genes, enabling targeted surveillance, risk-reducing strategies, and personalized treatment plans. For individuals with a family history of breast cancer or known genetic mutations, genetic counselling is crucial. Genetic counsellors provide information about the implications of genetic test results, guide decision-making regarding preventive measures (such as prophylactic mastectomy or oophorectomy), and offer psychological support [5].

Description

Breast cancer typically begins in the cells of the ducts or lobules of the breast. Ductal carcinoma originates in the milk ducts, while lobular carcinoma starts in the lobules, the milk-producing glands. The disease can be classified into various types based on the specific characteristics of the cancer cells, such as hormone receptor status and HER2 status. The progression of breast cancer involves a series of stages, from localized tumours to more advanced forms that may spread to other parts of the body. Understanding genetic predispositions to breast cancer allows for the implementation of preventive strategies. For high-risk individuals, options include increased surveillance (such as regular mammograms and MRI screenings), chemoprevention (using medications like tamoxifen or raloxifene), and prophylactic surgeries. Moreover, knowledge of genetic mutations can influence treatment decisions. For example, PARP inhibitors are a class of drugs that have shown efficacy in treating breast cancers associated with ductal carcinoma and lobules of the breast mutations. These drugs exploit the defective DNA repair mechanisms in cancer cells, leading to cell death.

Conclusion

Genetic predispositions play a pivotal role in the development of breast cancer. High-penetrance genes such as ductal carcinoma, lobules of the breast, and TP53 significantly increase the risk, while moderate- and low-penetrance genes contribute to varying extents. Advances in genetic testing and counselling have revolutionized the management of hereditary breast cancer, offering opportunities for early detection, personalized prevention, and targeted therapies. As research continues, a deeper understanding of genetic predispositions will further enhance our ability to combat breast cancer effectively.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Hwang, E. Shelley, Peter Beitsch, Peter Blumencranz and David Carr, et al. "Clinical impact of intraoperative margin assessment in breast-conserving surgery with a novel peguliclanine fluorescence-guided system: A nonrandomized controlled trial." *JAMA Surg* 157 (2022): 573-580.
2. Davis, Scott C., Summer L. Gibbs, Jason R. Gunn and Brian W. Pogue. "Topical dual-stain difference imaging for rapid intra-operative tumor identification in fresh specimens." *Opt Lett* 38 (2013): 5184-5187.

*Address for Correspondence: Luis Elian, Department of Medicine, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA; E-mail: elian@luis.sc.edu

Copyright: © 2024 Elian L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 03 July, 2024, Manuscript No. jio-24-145782; Editor Assigned: 05 July, 2024, PreQC No. P-145782; Reviewed: 17 July, 2024, QC No. Q-145782; Revised: 22 July, 2024, Manuscript No. R-145782; Published: 29 July, 2024, 10.37421/2329-6771.2024.13.498

3. Webb, Bradley A., Michael Chimenti, Matthew P. Jacobson and Diane L. Barber. "Dysregulated pH: A perfect storm for cancer progression." *Nat Rev Cancer* 11 (2011): 671-677.
4. Walker, Josephine, Betty B. Chaar, Numa Vera and Alvish S. Pillai, et al. "Medicine shortages in Fiji: A qualitative exploration of stakeholders' views." *PLoS One* 12: e0178429.
5. Placzek, W. J., J. Wei, S. Kitada and D. Zhai, et al. "A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy." *Cell Death Dis* 1 (2010): e40-e40.

How to cite this article: Elían, Luis. "Genetic Factors and their Impact on Breast Cancer Risk." *J Integr Oncol* 13 (2024): 498.